NYSE:ABBV

AbbVie - ABBV Stock Forecast, Price & News

$134.21

-8.51 (-5.96%)

(As of 09/30/2022 12:00 AM ET)

Add

Compare

Today's Range: $134.09
▼
$142.33
50-Day Range: $134.21
▼
$151.15
52-Week Range: $106.86
▼
$175.91

Volume: 15.36 million shs
Average Volume: 5.28 million shs
Market Capitalization: $237.30 billion

P/E Ratio: 19.01
Dividend Yield: 3.95%
Price Target: $159.35

AbbVie MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 18.7% Upside
$159.35 Price Target
Short Interest: Healthy
0.73% of Shares Sold Short
Dividend Strength: Strong
Based on Four Factors
Sustainability: -2.34
Upright™ Environmental Score
News Sentiment: 0.26
Based on 19 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: -16.01%
From $14.05 to $11.80 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.38 out of 5 stars

Medical Sector

302nd out of 1,095 stocks

Pharmaceutical Preparations Industry

133rd out of 547 stocks

2.3

Analyst's Opinion

Consensus Rating
AbbVie has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 9 buy ratings, 6 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $159.35, AbbVie has a forecasted upside of 18.7% from its current price of $134.21.
Amount of Analyst Coverage
AbbVie has only been the subject of 4 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.73% of the outstanding shares of AbbVie have been sold short.
Short Interest Ratio / Days to Cover
AbbVie has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in AbbVie has recently increased by 13.80%, indicating that investor sentiment is decreasing significantly.

4.2

Dividend Strength

Dividend Leadership
AbbVie is a leading dividend payer. It pays a dividend yield of 3.95%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
AbbVie has been increasing its dividend for 50 years.
Dividend Coverage
The dividend payout ratio of AbbVie is 79.89%. Payout ratios above 75% are not desirable because they may not be sustainable.
Dividend Sustainability
Based on earnings estimates, AbbVie will have a dividend payout ratio of 47.80% next year. This indicates that AbbVie will be able to sustain or increase its dividend.

3.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
AbbVie has received a 52.25% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Adalimumab", "Ibrutinib", and "Hepatitis medication" products. See details.
Environmental Sustainability
The Environmental Impact score for AbbVie is -2.34.

1.8

News and Social Media Coverage

News Sentiment
AbbVie has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.83 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 19 news articles for AbbVie this week, compared to 18 articles on an average week.
Search Interest
Only 234 people have searched for ABBV on MarketBeat in the last 30 days. This is a decrease of -12% compared to the previous 30 days.
MarketBeat Follows
Only 87 people have added AbbVie to their MarketBeat watchlist in the last 30 days. This is a decrease of -30% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AbbVie insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.08% of the stock of AbbVie is held by insiders.
Percentage Held by Institutions
68.25% of the stock of AbbVie is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for AbbVie are expected to decrease by -16.01% in the coming year, from $14.05 to $11.80 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of AbbVie is 19.01, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 113.68.
Price to Earnings Ratio vs. Sector
The P/E ratio of AbbVie is 19.01, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 78.93.
Price to Earnings Growth Ratio
AbbVie has a PEG Ratio of 4.01. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
AbbVie has a P/B Ratio of 15.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About AbbVie (NYSE:ABBV) Stock

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Receive ABBV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter.

ABBV Stock News Headlines

October 1, 2022 | finance.yahoo.com

How Far Will AbbVie's Humira Revenue Fall in 2023?

October 1, 2022 | fool.com

Here's Why This Dividend King Is a Buy - The Motley Fool

October 1, 2022 | finance.yahoo.com

Here's Why This Dividend King Is a Buy

September 30, 2022 | benzinga.com

7 Analysts Have This to Say About AbbVie - AbbVie (NYSE:ABBV) - Benzinga

September 30, 2022 | seekingalpha.com

ABBV stock pares losses as SVB Leerink retracts guidance claims (NYSE:ABBV) - Seeking Alpha

September 30, 2022 | cnbc.com

We're upgrading our rating on AbbVie amid a false report on the biopharma's guidance - CNBC

September 30, 2022 | stocknews.com

3 Safe Stocks You'll Want to Have Exposure to in 2022

September 30, 2022 | benzinga.com

Analyzing AbbVie's Short Interest - AbbVie (NYSE:ABBV) - Benzinga

September 30, 2022 | seekingalpha.com

AbbVie pares losses as SVB Leerink retracts guidance claims

September 30, 2022 | fool.com

Where Will AbbVie Be in 3 Years? - The Motley Fool

September 30, 2022 | finance.yahoo.com

Where Will AbbVie Be in 3 Years?

September 29, 2022 | finance.yahoo.com

AbbVie Highlights Robust Gastroenterology Portfolio with New Data in Crohn's Disease and Ulcerative Colitis at the UEG Week 2022

September 28, 2022 | finance.yahoo.com

AbbVie Inc. (NYSE:ABBV) is a favorite amongst institutional investors who own 70%

September 28, 2022 | fool.com

2 High-Yielding Dividend Stocks That Could Raise Their Payouts in October - The Motley Fool

September 27, 2022 | finance.yahoo.com

XEN® 63 Gel Implant available now for patients with primary open angle glaucoma where previous medical treatments have failed

September 26, 2022 | benzinga.com

Check Out What Whales Are Doing With ABBV - AbbVie (NYSE:ABBV) - Benzinga

September 26, 2022 | stocknews.com

3 Stocks to Get Bullish on Right Now

September 26, 2022 | finance.yahoo.com

AbbVie Stock Is One To Watch As It Sees RS Rating Jump To 91

September 24, 2022 | finance.yahoo.com

AbbVie Inc.'s (NYSE:ABBV) Business Is Trailing The Market But Its Shares Aren't - Yahoo Finance

September 24, 2022 | fool.com

Is AbbVie a Buy? - The Motley Fool

September 24, 2022 | finance.yahoo.com

AbbVie Inc.'s (NYSE:ABBV) Business Is Trailing The Market But Its Shares Aren't

September 23, 2022 | fool.com

Got $1,000? 2 Stocks That Could Be Bargain Buys For 2022 and Beyond - The Motley Fool

September 23, 2022 | nasdaq.com

What Could This Drug News Mean for AbbVie? - Nasdaq

September 23, 2022 | finance.yahoo.com

Got $1,000? 2 Stocks That Could Be Bargain Buys For 2022 and Beyond

September 23, 2022 | fool.com

What Could This Drug News Mean for AbbVie? - The Motley Fool

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ABBV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter.

ABBV Company Calendar

Ex-Dividend for 8/15 Dividend: 7/14/2022
Last Earnings: 7/29/2022
Dividend Payable: 8/15/2022
Today: 10/02/2022
Ex-Dividend for 11/15 Dividend: 10/13/2022
Next Earnings (Estimated): 11/04/2022
Dividend Payable: 11/15/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Sector: Medical
Current Symbol: NYSE:ABBV
CUSIP: 00287Y10
CIK: 1551152
Web: www.abbvie.com
Phone: (847) 932-7900
Fax: 302-655-5049
Employees: 50,000
Year Founded: 2013

Price Target and Rating

Average Stock Price Forecast: $159.35
High Stock Price Forecast: $200.00
Low Stock Price Forecast: $135.00
Forecasted Upside/Downside: +18.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 16 Analysts

Profitability

EPS (Most Recent Fiscal Year): $7.06
Trailing P/E Ratio: 19.01
Forward P/E Ratio: 9.55
P/E Growth: 4.01
Net Income: $11.54 billion
Net Margins: 22.03%
Pretax Margin: 24.54%
Return on Equity: 158.41%
Return on Assets: 16.34%

Debt

Debt-to-Equity Ratio: 4.15
Current Ratio: 0.84
Quick Ratio: 0.75

Sales & Book Value

Annual Sales: $56.20 billion
Price / Sales: 4.22
Cash Flow: $16.61 per share
Price / Cash Flow: 8.08
Book Value: $8.73 per share
Price / Book: 15.37

Miscellaneous

Outstanding Shares: 1,768,100,000
Free Float: 1,766,683,000
Market Cap: $237.30 billion
Optionable: Optionable
Beta: 0.72

Social Links

Key Executives

Mr. Richard A. Gonzalez (Age 68)
Chairman & CEO
Comp: $7.42M

Mr. Robert A. Michael (Age 52)
Vice Chairman & Pres
Comp: $3.82M

Ms. Laura J. Schumacher (Age 59)
Vice Chairman of External Affairs, Chief Legal Officer & Corp. Sec.
Comp: $4.18M

Mr. Jeffrey Ryan Stewart (Age 53)
Exec. VP & Chief Commercial Officer
Comp: $3.25M

Mr. Scott T. Reents (Age 55)
Sr. VP & CFO

Dr. Azita Saleki-Gerhardt Ph.D. (Age 59)
Exec. VP of Operations

Dr. Thomas J. Hudson (Age 60)
Sr. VP of R&D and Chief Scientific Officer

Ms. Elizabeth Shea
VP of Investor Relations

Mr. Timothy J. Richmond (Age 56)
Exec. VP & Chief HR Officer

Mr. Henry O. Gosebruch (Age 49)
Exec. VP & Chief Strategy Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ABBV Stock - Frequently Asked Questions

Should I buy or sell AbbVie stock right now?: 16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last twelve months. There are currently 1 sell rating, 6 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ABBV shares.
View ABBV analyst ratings or view top-rated stocks.
What is AbbVie's stock price forecast for 2022?: 16 equities research analysts have issued 12-month target prices for AbbVie's shares. Their ABBV share price forecasts range from $135.00 to $200.00. On average, they expect the company's share price to reach $159.35 in the next twelve months. This suggests a possible upside of 18.7% from the stock's current price.
View analysts price targets for ABBV or view top-rated stocks among Wall Street analysts.
How have ABBV shares performed in 2022?: AbbVie's stock was trading at $135.40 at the beginning of 2022. Since then, ABBV stock has decreased by 0.9% and is now trading at $134.21.
View the best growth stocks for 2022 here.
Are investors shorting AbbVie?: AbbVie saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 12,950,000 shares, an increase of 13.8% from the August 31st total of 11,380,000 shares. Based on an average daily volume of 5,430,000 shares, the short-interest ratio is currently 2.4 days.
View AbbVie's Short Interest.
When is AbbVie's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, November 4th 2022.
View our ABBV earnings forecast.
How were AbbVie's earnings last quarter?: AbbVie Inc. (NYSE:ABBV) issued its earnings results on Friday, July, 29th. The company reported $3.51 EPS for the quarter, topping the consensus estimate of $3.42 by $0.09. The firm earned $14.58 billion during the quarter, compared to analyst estimates of $14.64 billion. AbbVie had a net margin of 22.03% and a trailing twelve-month return on equity of 158.41%. The firm's quarterly revenue was up 4.5% compared to the same quarter last year. During the same period last year, the firm earned $3.11 EPS.
Read the conference call transcript.
How often does AbbVie pay dividends? What is the dividend yield for AbbVie?: AbbVie announced a quarterly dividend on Friday, September 9th. Shareholders of record on Friday, October 14th will be paid a dividend of $1.41 per share on Tuesday, November 15th. This represents a $5.64 dividend on an annualized basis and a dividend yield of 4.20%. The ex-dividend date of this dividend is Thursday, October 13th.
Read our dividend analysis for ABBV.
Is AbbVie a good dividend stock?: AbbVie (NYSE:ABBV) pays an annual dividend of $5.64 per share and currently has a dividend yield of 3.95%. The company has been increasing its dividend for 50 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 79.89%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, ABBV will have a dividend payout ratio of 47.80% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for ABBV.

What guidance has AbbVie issued on next quarter's earnings?: AbbVie issued an update on its third quarter 2022 earnings guidance on Monday, August, 8th. The company provided earnings per share (EPS) guidance of $3.55-$3.59 for the period, compared to the consensus EPS estimate of $3.67. The company issued revenue guidance of $14.80 billion-$14.80 billion, compared to the consensus revenue estimate of $15.28 billion.
What is Richard A. Gonzalez's approval rating as AbbVie's CEO?: 580 employees have rated AbbVie Chief Executive Officer Richard A. Gonzalez on Glassdoor.com. Richard A. Gonzalez has an approval rating of 88% among the company's employees.
What other stocks do shareholders of AbbVie own?: Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), AT&T (T), Bristol-Myers Squibb (BMY), Wheaton Precious Metals (WPM), Rogers Communications (RCI) and Open Text (OTEX).
What is AbbVie's stock symbol?: AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."
How do I buy shares of AbbVie?: Shares of ABBV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is AbbVie's stock price today?: One share of ABBV stock can currently be purchased for approximately $134.21.
How much money does AbbVie make?: AbbVie (NYSE:ABBV) has a market capitalization of $237.30 billion and generates $56.20 billion in revenue each year. The company earns $11.54 billion in net income (profit) each year or $7.06 on an earnings per share basis.
How many employees does AbbVie have?: The company employs 50,000 workers across the globe.
Does AbbVie have any subsidiaries?: The following companies are subsidiares of AbbVie: AbbVie (Gibraltar) Holdings Limited, AbbVie (Gibraltar) Holdings Limited Luxembourg S.C.S., AbbVie (Gibraltar) Limited, AbbVie (Pty) Ltd., AbbVie A/S, AbbVie AB, AbbVie AG, AbbVie AS, AbbVie Australasia Holdings Limited, AbbVie B.V., AbbVie Bahamas Ltd., AbbVie Biofarmacevtska družba d.o.o., AbbVie Biopharmaceuticals GmbH, AbbVie Biopharmaceuticals LLC, AbbVie Biopharmaceuticals Ltd., AbbVie Bioresearch Center Inc., AbbVie Biotech Ventures Inc., AbbVie Biotechnology GmbH, AbbVie Biotechnology Ltd, AbbVie Biotherapeutics Inc., AbbVie Biotherapeutics Limited, AbbVie Central Finance B.V., AbbVie Corp, AbbVie Corporation, AbbVie Deutschland GmbH & Co. KG, AbbVie EOOD, AbbVie Endocrine Inc., AbbVie Endocrinology Inc., AbbVie Farmacéuticos S.A. de C.V., AbbVie Farmacêutica Ltda., AbbVie Finance B.V., AbbVie Finance Corporation, AbbVie Finance LLC, AbbVie GK, AbbVie GmbH, AbbVie Holdings Corporation, AbbVie Holdings Inc., AbbVie Holdings KK, AbbVie Holdings SAS, AbbVie Holdings Unlimited, AbbVie Holdings s.r.o., AbbVie International S.à r.l., AbbVie Investments Limited, AbbVie Investments S.à r.l., AbbVie Ireland Holdings Limited, AbbVie Ireland NL B.V., AbbVie Ireland Unlimited Company, AbbVie Japan Holdings B.V., AbbVie Kft., AbbVie Komplementär GmbH, AbbVie L.L.C., AbbVie L.da, AbbVie Limited, AbbVie Limited Liability Company, AbbVie Logistics B.V., AbbVie Ltd, AbbVie Ltd., AbbVie Manufacturing Management Limited, AbbVie Nederland Holdings B.V., AbbVie Operations Singapore Pte. Ltd., AbbVie Overseas S.à r.l., AbbVie Oy, AbbVie Participações Ltda., AbbVie Pharmaceutical Trading (Shanghai) Co. Ltd., AbbVie Pharmaceuticals B.V., AbbVie Pharmaceuticals GmbH, AbbVie Pharmaceuticals LLC, AbbVie Pharmaceuticals SCA., AbbVie Pharmaceuticals Societe Anonyme, AbbVie Polska Sp. z o.o., AbbVie Productos Farmacéuticos Limitada, AbbVie Products LLC, AbbVie Promoção L.da, AbbVie Pte. Ltd., AbbVie Pty Ltd, AbbVie Purchasing LLC, AbbVie Real Estate Management GmbH, AbbVie Research B.V., AbbVie Resources Inc., AbbVie Resources International Inc., AbbVie Respiratory LLC, AbbVie S. de R.L., AbbVie S.A., AbbVie S.A., AbbVie S.A.S., AbbVie S.R.L., AbbVie S.r.l., AbbVie S.à r.l., AbbVie SA, AbbVie SAS, AbbVie SIA, AbbVie Sarl, AbbVie Sdn. Bhd., AbbVie Sp. z o.o., AbbVie Spain S.L., AbbVie Stemcentrx LLC, AbbVie Trading S.R.L., AbbVie Trustee Company Limited, AbbVie Tıbbi İlaçlar Sanayi ve Ticaret Limited Şirketi, AbbVie UAB, AbbVie UK Biopharmaceuticals Ltd, AbbVie UK Holdco Limited, AbbVie UK Ltd, AbbVie US Holdings LLC, AbbVie US LLC, AbbVie Venezuela B.V., AbbVie Venezuela Holdings B.V., AbbVie Ventures LLC, AbbVie d.o.o., AbbVie s.r.o., Aeropharm Technology LLC, Allergan, BioDisplay Technologies Inc., Fournier Laboratories Ireland Ltd., Fremont Holding L.L.C., Fundación AbbVie, IEP Pharmaceutical Devices LLC, ImmuVen, KOS Pharmaceuticals Inc., Knoll LLC, Knoll Pharmaceutical Company, Life Properties Inc., Mavupharma, Organics L.L.C., Pharmacyclics (Europe) Limited, Pharmacyclics (Shanghai) Management Consulting Services Limited, Pharmacyclics Cayman Ltd., Pharmacyclics Inc, Pharmacyclics LLC, Pharmacyclics Switzerland GmbH, Rowell Laboratories Inc., S.C. AbbVie S.R.L., Sapphire Merger Sub Inc., Stem CentRx, Stemcentrx Cayman Ltd., Suffolk Merger Sub Inc., and Unimed Pharmaceuticals LLC.
Read More
How can I contact AbbVie?: AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The official website for the company is www.abbvie.com. The company can be reached via phone at (847) 932-7900 or via fax at 302-655-5049.

This page (NYSE:ABBV) was last updated on 10/2/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

AbbVie - ABBV Stock Forecast, Price & News

AbbVie MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows